Nippon Life Global Investors Americas’s Charles River Laboratories CRL Stock Holding History

Nippon Life Global Investors Americas’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-22,250	Closed	-$4.6M	–	108
2024 Q2	$4.6M	Hold	22,250	–	–	0.2%	67
2024 Q1	$6.03M	Buy	22,250 +17,630	+382%	+$4.21M	0.28%	63
2023 Q4	$1.09M	Hold	4,620	–	–	0.06%	108
2023 Q3	$905K	Hold	4,620	–	–	0.06%	114
2023 Q2	$971K	Hold	4,620	–	–	0.07%	112
2023 Q1	$932K	Hold	4,620	–	–	0.06%	114
2022 Q4	$1.01M	Buy	+4,620	New	+$1.01M	0.07%	111

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Nippon Life Global Investors Americas's CRL Position: Q3 2024 in Review

Nippon Life Global Investors Americas sold out of Charles River Laboratories (CRL) in Q3 2024, closing a stake of 22,250 shares — an estimated $4.6M sold.

Nippon Life Global Investors Americas first reported a position in CRL in Q4 2022 and held it in 7 quarters. The position peaked at $6.03M in Q1 2024. 628 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

Nippon Life Global Investors Americas reported no remaining Charles River Laboratories position as of Q3 2024 after selling out during the quarter.
Nippon Life Global Investors Americas sold 22,250 Charles River Laboratories shares in Q3 2024, an estimated $4.6M.
Nippon Life Global Investors Americas first reported a position in Charles River Laboratories in Q4 2022 and held it in 7 quarters.
Nippon Life Global Investors Americas's Charles River Laboratories position peaked at $6.03M in Q1 2024.
628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on Nippon Life Global Investors Americas's 13F filing for Q3 2024, filed 14 Nov 2024.